Hepatitis C Infection in the Elderly

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3170-3180

  Saab, Sammy ^a   Rheem, Justin ^b   Sundaram, Vinay ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Elderly; Hepatitis C; Systematic review

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON;

AGED; ANTIVIRAL THERAPY; DISEASE TRANSMISSION; GENOTYPE; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; INFECTION RISK; MEDICAL HISTORY; PRIORITY JOURNAL; REVIEW; UNITED STATES; AGE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; RISK FACTOR; TIME; TRANSMISSION; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945495814     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3717-6     Document Type: Review

References (93)

1. Ortman JM, Velkoff VA, Hogan H. An aging nation: The older population in the United States, current population reports. Washington, DC: U.S. Census Bureau; 2014:25–1140.
2. U.S. Census Bureau. 65+ in the United States: 2010. Washington, DC: U.S. Government Printing Office; 2014:23–212.
3. United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2013. ST/ESA/SER.A/348; 2013.
4. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med Sci. 2013;68:667–674.
5. Singh S, Bajorek B. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy. Pharm Pract. 2014;12:489.
6. Cronan JJ. Retirement: it’s not about the finances! J Am Coll Radiol. 2009;6:242–245.
7. World Health Organization. Definition of an older or elderly person. Geneva, Switzerland: WHO. http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html; 2010. Accessed January 30, 2015.
8. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic Hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.
9. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102:1383–1391.
10. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int. 2010;30:527–537.
11. Roeder C, Jordan S, Schulze Zur Wiesch J, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20:10984–10993.
12. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
13. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the U.S., 1999 through 2002. Ann Intern Med. 2006;144:705–714.
14. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.
15. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60:691–698.
16. Chak E, Saab S. Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response. Curr Hepat Rep. 2010;9:147–154.
17. Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006;20:589–592.
18. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl. 2007;13:1032–1038.
19. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39:668–673.
20. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19:1312–1317.
21. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis. 2003;37:S315–S322.
22. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010;153:231–239.
23. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292:767–770.
24. Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med. 2014;47:233–241.
25. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
26. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol. 2014;109:1576–1584.
27. Magiorkinis G, Magiorkinis E, Paraskevis D, et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med. 2009;6:e1000198.
28. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84:1744–1750.
29. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995;122:161–168.
30. Brind AM, Watson JP, James OF, Bassendine MF. Hepatitis C virus infection in the elderly. QJM. 1996;89:291–296.
31. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260–1267.
32. D’Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol. 2005;3:910–917.
33. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:764–767.
34. Deuffic S, Buffat L, Poynard T, Vallera AJ. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999;29:1596–1601.
35. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47–S56.
36. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000;20:47–55.
37. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99:4588–4591.
38. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463–1466.
39. Ohishi W, Kitamoto M, Aikata H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol. 2003;38:894–900.
40. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.
41. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–1491.
42. Davila JA, Morgan RO, Shaib Y, McLynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372–1380.
43. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748–755.
44. Kainuma M, Furusyo N, Kajiwara E, et al. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol. 2010;16:4400–4409.
45. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751–759.
46. Oze T, Hiramatsu N, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol. 2011;54:604–611.
47. Nishikawa H, Iguchi E, Koshikawa Y, et al. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes. 2012;5:135.
48. Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW. Treatment response and tolerability of pegylated interferon-a plus ribavirin combination therapy in elderly patients (≥65 years) with chronic hepatitis C in Korea. Hepat Mon. 2012;12:430–436.
49. Yu JW, Sun LJ, Kang P, Yan BZ, Zhao YH. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2012;11:185–192.
50. Hu CC, Lin CL, Kuo YL, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37:81–90.
51. Frei P, Leucht AK, Kofmehl R, et al. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-a and ribavirin in chronic hepatitis c virus patients. Liver Int. 2013;34:551–557.
52. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–212.
53. Fujino H, Imamura M, Nagaoki Y, et al. Hiroshima Liver Study Group. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol. 2014;49:1548–1556.
54. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
55. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762–768.
56. Zeuzem S, Dusheiko GM, Salupere R, et al. VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
57. Jacobson IM, Gordon SC, Kowdley KV, et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
58. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
59. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
60. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
61. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
62. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.
63. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–232.
64. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–1303.
65. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838.
66. Harvoni [package insert]. Foster City, CA: Gilead Sciences Inc; 2015.
67. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2015.
68. Viekira pak [package insert]. North Chicago, IL: AbbVie Inc; 2014.
69. Chien NT, Dundoo G, Horani MH, Osmack P, Morley JH, Di Bisceglie AM. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc. 1999;47:1110–1113.
70. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562.
71. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–1101.
72. Monica F, Lirussi F, Pregun I, et al. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis. 2006;38:336–340.
73. Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308–315.
74. Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL. VA HCV-001 Study Group. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci. 2008;53:809–814.
75. Schmucker DL, Sachs H. Quantifying dense bodies and lipofuscin during aging: a morphologist’s perspective. Arch Gerontol Geriatr. 2002;34:249–261.
76. Jung T, Bader N, Grune T. Lipofuscin: formation, distribution, and metabolic consequences. Ann NY Acad Sci. 2007;1119:97–111.
77. Jolly RD, Douglas BV, Davey PM, Roiri JE. Lipofuscin in bovine muscle and brain: a model for studying age pigment. Gerontology. 1995;41:283–295.
78. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297–301.
79. Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res. 2011;2011:526379.
80. Ono Y, Kawachi S, Hayashida T, et al. The influence of donor age on liver regeneration and hepatic progenitor cell populations. Surgery. 2011;150:154–161.
81. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11:537–550.
82. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–295.
83. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res Rev. 2011;10:330–335.
84. García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Analyzed the relationship of vitamin D status with advanced liver fibrosis in CHC treatment naive patients and sustained virologic response in CHC patients on pegs late interferon alpha plus ribavirin therapy. Hepatology. 2014;60:1541–1550.
85. Horlick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
86. Ding N, Yu RT, Subramaniam N, et al. A vitamin d receptor/SMAD genomic circuit gates hepatic fibrosis response. Cell. 2013;153:601–613.
87. Gascon-Barré M, Demers C, Mirshahi A, Néron S, Zalzal S, Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology. 2003;37:1034–1042.
88. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40:1426–1433.
89. Codes L, Asselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. 2007;56:390–395.
90. Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011;140:818–829.
91. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–419.
92. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397–406.
93. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed April 21, 2015.